# | Title | Journal | Year | Citations |
---|
|
1 | Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes | Diabetes, Obesity and Metabolism | 2013 | 679 |
2 | Pancreatic β‐cell mass in European subjects with type 2 diabetes | Diabetes, Obesity and Metabolism | 2008 | 672 |
3 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial | Diabetes, Obesity and Metabolism | 2007 | 605 |
4 | Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c | Diabetes, Obesity and Metabolism | 2010 | 597 |
5 | Adiponectin – a key adipokine in the metabolic syndrome | Diabetes, Obesity and Metabolism | 2006 | 548 |
6 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Diabetes, Obesity and Metabolism | 2013 | 545 |
7 | Incretin hormones: Their role in health and disease | Diabetes, Obesity and Metabolism | 2018 | 514 |
8 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors | Diabetes, Obesity and Metabolism | 2012 | 491 |
9 | Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women | Diabetes, Obesity and Metabolism | 2006 | 486 |
10 | Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin | Diabetes, Obesity and Metabolism | 2007 | 481 |
11 | Insulin‐associated weight gain in diabetes – causes, effects and coping strategies | Diabetes, Obesity and Metabolism | 2007 | 457 |
12 | Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Diabetes, Obesity and Metabolism | 2013 | 436 |
13 | Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Diabetes, Obesity and Metabolism | 2011 | 434 |
14 | Role of vitamin D in the pathogenesis of type 2 diabetes mellitus | Diabetes, Obesity and Metabolism | 2008 | 419 |
15 | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia | Diabetes, Obesity and Metabolism | 2012 | 409 |
16 | COVID‐19 infection may cause ketosis and ketoacidosis | Diabetes, Obesity and Metabolism | 2020 | 409 |
17 | Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2015 | 403 |
18 | Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2006 | 399 |
19 | Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin | Diabetes, Obesity and Metabolism | 2014 | 398 |
20 | Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis | Diabetes, Obesity and Metabolism | 2016 | 370 |
21 | Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis | Diabetes, Obesity and Metabolism | 2018 | 355 |
22 | Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity | Diabetes, Obesity and Metabolism | 2007 | 353 |
23 | Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes | Diabetes, Obesity and Metabolism | 2012 | 352 |
24 | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial | Diabetes, Obesity and Metabolism | 2011 | 350 |
25 | An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines | Diabetes, Obesity and Metabolism | 2020 | 338 |
26 | Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors | Diabetes, Obesity and Metabolism | 2016 | 336 |
27 | Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis | Diabetes, Obesity and Metabolism | 2020 | 335 |
28 | Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial | Diabetes, Obesity and Metabolism | 2014 | 326 |
29 | Advanced glycation endproducts: what is their relevance to diabetic complications? | Diabetes, Obesity and Metabolism | 2007 | 320 |
30 | Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity | Diabetes, Obesity and Metabolism | 2017 | 320 |
31 | Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis | Diabetes, Obesity and Metabolism | 2017 | 318 |
32 | Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials | Diabetes, Obesity and Metabolism | 2011 | 313 |
33 | Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials | Diabetes, Obesity and Metabolism | 2013 | 312 |
34 | Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature | Diabetes, Obesity and Metabolism | 2010 | 299 |
35 | Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls | Diabetes, Obesity and Metabolism | 2014 | 298 |
36 | The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus | Diabetes, Obesity and Metabolism | 2012 | 290 |
37 | Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes | Diabetes, Obesity and Metabolism | 2012 | 289 |
38 | Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2010 | 284 |
39 | Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial | Diabetes, Obesity and Metabolism | 2011 | 276 |
40 | GLP‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence | Diabetes, Obesity and Metabolism | 2013 | 276 |
41 | Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial | Diabetes, Obesity and Metabolism | 2009 | 273 |
42 | New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3) | Diabetes, Obesity and Metabolism | 2015 | 272 |
43 | Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study | Diabetes, Obesity and Metabolism | 2011 | 267 |
44 | Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects | Diabetes, Obesity and Metabolism | 2011 | 267 |
45 | Diabetes is an inflammatory disease: evidence from traditional Chinese medicines | Diabetes, Obesity and Metabolism | 2011 | 266 |
46 | Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review | Diabetes, Obesity and Metabolism | 2018 | 266 |
47 | Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study | Diabetes, Obesity and Metabolism | 2007 | 263 |
48 | Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials | Diabetes, Obesity and Metabolism | 2018 | 262 |
49 | Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy | Diabetes, Obesity and Metabolism | 2009 | 261 |
50 | Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease | Diabetes, Obesity and Metabolism | 2019 | 261 |